MX386938B - Moduladores del receptor nmda espiro-lactam y uso de los mismos. - Google Patents

Moduladores del receptor nmda espiro-lactam y uso de los mismos.

Info

Publication number
MX386938B
MX386938B MX2019001321A MX2019001321A MX386938B MX 386938 B MX386938 B MX 386938B MX 2019001321 A MX2019001321 A MX 2019001321A MX 2019001321 A MX2019001321 A MX 2019001321A MX 386938 B MX386938 B MX 386938B
Authority
MX
Mexico
Prior art keywords
nmda
spiro
receptor modulators
compounds
lactam receptor
Prior art date
Application number
MX2019001321A
Other languages
English (en)
Spanish (es)
Other versions
MX2019001321A (es
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of MX2019001321A publication Critical patent/MX2019001321A/es
Publication of MX386938B publication Critical patent/MX386938B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499Spiro-condensed pyrazines or piperazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2019001321A 2016-08-01 2017-08-01 Moduladores del receptor nmda espiro-lactam y uso de los mismos. MX386938B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662369456P 2016-08-01 2016-08-01
PCT/US2017/044841 WO2018026782A1 (en) 2016-08-01 2017-08-01 Spiro-lactam nmda receptor modulators and uses thereof

Publications (2)

Publication Number Publication Date
MX2019001321A MX2019001321A (es) 2019-07-04
MX386938B true MX386938B (es) 2025-03-19

Family

ID=59593191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001321A MX386938B (es) 2016-08-01 2017-08-01 Moduladores del receptor nmda espiro-lactam y uso de los mismos.

Country Status (17)

Country Link
US (3) US10918637B2 (enExample)
EP (1) EP3490993B1 (enExample)
JP (1) JP7032378B2 (enExample)
KR (1) KR102465757B1 (enExample)
CN (1) CN109890825B (enExample)
AU (1) AU2017305240B2 (enExample)
CA (1) CA3031539C (enExample)
CL (1) CL2019000247A1 (enExample)
CO (1) CO2019000943A2 (enExample)
EA (1) EA201990428A1 (enExample)
ES (1) ES2973283T3 (enExample)
IL (2) IL286107B2 (enExample)
MX (1) MX386938B (enExample)
PE (1) PE20190504A1 (enExample)
PH (1) PH12019500206A1 (enExample)
SG (1) SG11201900551WA (enExample)
WO (1) WO2018026782A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
ES2935352T3 (es) 2013-01-29 2023-03-06 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
KR101518972B1 (ko) 2014-08-01 2015-05-18 제이더블유크레아젠 주식회사 수지상세포의 제조방법, 이에 의해 제조된 수지상세포 및 그 용도
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムnmda受容体修飾因子及びその使用
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
CA3031563C (en) 2016-08-01 2023-12-05 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
SG11202007256PA (en) 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
MX2022015168A (es) 2020-06-03 2023-01-16 Aptinyx Inc Compuestos de espirolactama y metodos para tratar infecciones virales usando los mismos.

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (en) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthesis of beta-lactam
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
ATE283278T1 (de) 1996-06-07 2004-12-15 Astrazeneca Ab Peptid derivate
US5959075A (en) 1996-08-02 1999-09-28 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
WO1999024584A1 (en) 1997-11-12 1999-05-20 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
AU782678B2 (en) 2000-02-01 2005-08-18 Agy Therapeutics, Inc. Interaction of NMDA receptor with protein tyrosine phosphatase
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
JP2004500874A (ja) 2000-06-22 2004-01-15 ニクシス ニューロセラピーズ インコーポレーティッド 低酸素症および関連状態の治療のための神経活性ペプチド
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
WO2002047535A2 (en) 2000-12-14 2002-06-20 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
AU2002248553A1 (en) 2001-03-07 2002-09-24 Cognetix, Inc Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
US20030022253A1 (en) 2001-07-25 2003-01-30 Nyxis Neurotherapies, Inc. Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
ATE451373T1 (de) 2002-07-05 2009-12-15 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1660634A4 (en) 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
WO2005020973A2 (en) 2003-08-29 2005-03-10 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
RS52471B (sr) 2005-03-24 2013-02-28 Emory University Režimi doziranja za lečenje traumatske povrede mozga progesteronom
EP1911753A1 (en) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
EP1945691A2 (en) 2005-08-26 2008-07-23 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US7884080B2 (en) 2006-09-15 2011-02-08 Schering Plough Corporation Azetidinone derivatives and methods of use thereof
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
US9783851B2 (en) 2008-02-20 2017-10-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
MX2010013946A (es) 2008-06-24 2011-02-15 Intervet Int Bv Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en ganado.
JP2011525521A (ja) 2008-06-27 2011-09-22 ノイロサーチ アクティーゼルスカブ 新規なテトラメチル置換ピペリジン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用
CA2732091A1 (en) 2008-08-07 2010-02-11 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2485751T3 (pl) 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
BR112012020142A2 (pt) 2010-02-11 2020-08-18 Northwestern University moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos.
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
AR082633A1 (es) 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP3679931A3 (en) 2011-04-27 2020-10-14 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
US9293690B2 (en) 2011-06-27 2016-03-22 Koninklijke Philips N.V. Ultrasound transducer assembly and method of manufacturing the same
DK3686194T3 (da) 2011-07-27 2021-11-22 Astrazeneca Ab 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
ES2935352T3 (es) 2013-01-29 2023-03-06 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
MX375286B (es) 2013-01-29 2025-03-06 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015018094A2 (pt) * 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
JP6419087B2 (ja) * 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体モジュレーターおよびその使用
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR102128675B1 (ko) 2016-05-19 2020-06-30 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
CA3031563C (en) 2016-08-01 2023-12-05 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムnmda受容体修飾因子及びその使用
PE20211455A1 (es) 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
SG11202007256PA (en) 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Also Published As

Publication number Publication date
EA201990428A1 (ru) 2019-08-30
AU2017305240B2 (en) 2021-12-09
JP7032378B2 (ja) 2022-03-08
PE20190504A1 (es) 2019-04-10
CN109890825B (zh) 2022-03-11
IL264495B (en) 2021-09-30
IL286107A (en) 2021-10-31
KR20190033594A (ko) 2019-03-29
CA3031539C (en) 2023-11-28
JP2019527234A (ja) 2019-09-26
US20230131402A1 (en) 2023-04-27
WO2018026782A1 (en) 2018-02-08
US20210322406A1 (en) 2021-10-21
AU2017305240A1 (en) 2019-02-28
EP3490993A1 (en) 2019-06-05
CA3031539A1 (en) 2018-02-08
ES2973283T3 (es) 2024-06-19
US10918637B2 (en) 2021-02-16
KR102465757B1 (ko) 2022-11-09
SG11201900551WA (en) 2019-02-27
EP3490993B1 (en) 2023-12-06
US20190175588A1 (en) 2019-06-13
CO2019000943A2 (es) 2019-02-08
US11376250B2 (en) 2022-07-05
EP3490993C0 (en) 2023-12-06
IL286107B1 (en) 2024-05-01
MX2019001321A (es) 2019-07-04
PH12019500206A1 (en) 2019-06-17
CL2019000247A1 (es) 2019-06-21
CN109890825A (zh) 2019-06-14
IL286107B2 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
MX383650B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX388786B (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
MX385336B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX378566B (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
MX386938B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX383292B (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof